Author Archives: Alice Melão, MSc

#ATS2018 – Start of Anti-Fibrotic Therapy in Newly Diagnosed IPF Patients Can Depend on Physician Preference, Survey Finds

A pulmonologist’s characteristics — such as the nature of the practice and previous treatment experience — can influence when anti-fibrotic therapy use is initiated in newly diagnosed idiopathic pulmonary fibrosis (IPF)  patients, a study based on a U.S. survey found. This finding adds to an understanding of the factors, besides patient preference,…

AdAlta Enhances, Renames Its Lead Candidate to Treat PF

AdAlta has changed the structure of its lead therapy candidate for AD-114, for the treatment of pulmonary fibrosis. The new product, renamed AD-214, has enhanced activity and improved stability compared to AD-114, allowing a better outcome, according to AdAlta. AD-214 retains key features of its precursor, as it…

Infant Lung Disease Shares Tissue-repair Signaling Problem with IPF, Study Finds

A lung-scarring disease that affects preterm infants has a tissue repair signaling problem seen in idiopathic pulmonary fibrosis, Vanderbilt University researchers report. The discovery increases scientists’ understanding of the mechanisms underlying bronchopulmonary dysplasia and IPF. It also raises the possibility of treating both disorders by targeting the signaling dysfunction. Researchers published…

Your PF Community

Woman laying down reading

Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.

View Forums